Physician profile
Jenna Evans
NPI 1821636606
$2,140.23
in general payments reported to CMS, 2019-2025
22 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $534 · 2023: $425 · 2024: $434 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.42 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $201.63 | 2022-2025 | |
| Abbvie INC. | $188.16 | 2022-2025 | |
| Amgen INC. | $178.13 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $175.30 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $156.40 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $146.87 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $124.84 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $123.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.49 | 2021-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $77.56 | 2021-2022 | |
| Esperion Therapeutics, INC. | $66.46 | 2021 | |
| Mylan Specialty L.P. | $39.72 | 2023-2024 | Yupelri |
| Amarin Pharma, INC. | $34.73 | 2021-2022 | |
| Dexcom, INC. | $34.48 | 2021-2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $26.16 | 2024 | Gemtesa |
| Seqirus USA INC | $22.49 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $21.97 | 2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.04 | 2022 | |
| Merck Sharp & Dohme LLC | $16.04 | 2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $15.41 | 2023 | Quviviq |
| Abbott Laboratories | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.